Ignite Creation Date:
2025-12-24 @ 5:57 PM
Ignite Modification Date:
2026-01-25 @ 7:53 PM
Study NCT ID:
NCT00617968
Status:
COMPLETED
Last Update Posted:
2009-09-02
First Post:
2008-02-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Sponsor:
Sanofi
Organization:
Study Overview
Official Title:
A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Consisting of Either a Docetaxel - Letrozole Combination or Letrozole Alone in Women Over 60 Years of Age Suffering From Grade I or II Operable Hormone Receptor-positive Breast Tumor.
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: